Intramuscular neridronate in postmenopausal women with low bone mineral density

Calcified Tissue International

Volumn 83, Issue 5, 2008, Pages 301-307

  Adami, Silvano ^a   Gatti, Davide ^a   Bertoldo, Francesco ^a   Sartori, Leonardo ^b   Di Munno, Ombretta ^c   Filipponi, Paolo ^d   Marcocci, Claudio ^c   Frediani, Bruno ^e   Palummeri, Ernesto ^f   Fiore, Carmelo Erio ^g   Costi, Daniele ^h   Rossini, Maurizio ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d Ospedale di Umbertide   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

^f GALLIERA HOSPITAL   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

Bisphosphonate; Bone mineral density; Bone turnover marker; Neridronate; Postmenopausal osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; NERIDRONIC ACID; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE MALAISE; INJECTION SITE MYALGIA; INJECTION SITE PAIN; INJECTION SITE PYREXIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BONE DENSITY; CALCIUM; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D;

EID: 58549093912     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-008-9179-5     Document Type: Article

References (22)

1. DM Black DE Thompson DC Bauer K Ensrud T Musliner MC Hochberg MC Nevitt S Suryawanshi SR Cummings Fracture Intervention Trial 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial FIT Research Group J Clin Endocrinol Metab 85 4118 4124
2. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier JY Reginster Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 333 340
3. CH Chesnut III A Skag C Christiansen R Recker JA Stakkestad A Hoiseth D Felsenberg H Huss J Gilbride RC Schimmer PD Delmas 2004 Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249
4. PD Delmas S Adami C Strugala JA Stakkestad JY Reginster D Felsenberg C Christiansen R Civitelli MK Drezner RR Recker M Bolognese C Hughes D Masanauskaite P Ward P Sambrook DM Reid 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study Arthritis Rheum 54 1838 1846
5. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings HORIZON Pivotal Fracture Trial 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822
6. M Rossini V Braga D Gatti D Gerardi N Zamberlan S Adami 1999 Intramuscular clodronate therapy in postmenopausal osteoporosis Bone 24 125 129
7. S Adami M Bevilacqua M Broggini P Filipponi S Ortolani E Palummeri F Ulivieri F Nannipieri V Braga 2002 Short-term intravenous therapy with neridronate in Paget's disease Clin Exp Rheumatol 20 55 58
8. S Adami D Gatti F Colapietro E Fracassi V Braga M Rossini L Tatò 2003 Intravenous neridronate in adults with osteogenesis imperfecta J Bone Miner Res 18 126 130
9. V Braga D Gatti F Colapietro E Battaglia D Righetti R Prizzi M Rossini S Adami 2003 Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis Bone 33 342 345
10. SL Hui SJ Gao XH Zhou XH Zhou CC Johnston Y Lu CC Gluer S Grampp H Genant 1997 Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments J Bone Miner Res 12 1463 1470
11. S Adami G Bianchi ML Brandi S Giannini S Ortolani O DiMunno B Frediani M Rossini on behalf of the BONTURNO study group 2008 Determinants of bone turnover markers in healthy premenopausal women Calcif Tissue Int 82 341 347
12. S Adami AK Bhalla R Dorizzi F Montesanti S Rosini G Salvagno V Lo Cascio 1987 The acute-phase response after bisphosphonate administration Calcif Tissue Int 41 326 331
13. CJ Rosen MC Hochberg SL Bonnick M McClung P Miller S Broy R Kagan E Chen RA Petruschke DE Thompson AE de Papp Fosamax Actonel Comparison Trial Investigators 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 151
14. JY Reginster S Adami P Lakatos M Greenwald JJ Stepan SL Silverman C Christiansen L Rowell N Mairon B Bonvoisin MK Drezner R Emkey D Felsenberg C Cooper PD Delmas PD Miller 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study Ann Rheum Dis 65 654 661
15. K Saag R Lindsay A Kriegman E Beamer W Zhou 2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density Bone 40 1238 1243
16. DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings FLEX Research Group 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2927 2938
17. MR McClung RD Wasnich DJ Hosking C Christiansen P Ravn M Wu AM Mantz J Yates PD Ross AC Santora 2nd Early Postmenopausal Intervention Cohort Study 2004 Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study J Clin Endocrinol Metab 89 4879 4885
18. D Michalská JJ Stepan BR Basson I Pavo 2006 The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 91 870 877
19. GH Nancollas R Tang RJ Phipps Z Henneman S Gulde W Wu A Mangood RG Russell FH Ebetino 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 617 627
20. S Adami JA Kanis 1995 Assessment of involutional bone loss: methodological and conceptual problems J Bone Miner Res 10 511 517
21. P Roschger S Rinnerthaler J Yates GA Rodan P Fratzl K Klaushofer 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women Bone 29 185 191
22. MA Brookhart J Avorn JN Katz JS Finkelstein M Arnold JM Polinski AR Patrick H Mogun DH Solmon 2007 Gaps in treatment among users of osteoporosis medications: the dynamics of non-compliance Am J Med 120 251 256